TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Spark Therapeutics, Inc. (NASDAQ: ONCE) Investor Lawsuit Against Acquisition Filed

  • Investors who purchased shares of Spark Therapeutics, Inc. (NASDAQ: ONCE) may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Spark Therapeutics, Inc.
Security
NASDAQ: ONCE

Case Name
Spark Therapeutics Deal Case
Type of Lawsuit
Mergers and Acquisition
Class Period Begin
Class Period End
You must register or login to receive notifications.

Click here to subscribe to Spark Therapeutics, Inc..
Summary

September 5, 2019 - The case was voluntarily dismissed.

March 11, 2019 - An investor, who currently holds shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), filed a lawsuit against the takeover of Spark Therapeutics, Inc. The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ: ONCE stockholders by agreeing to sell Spark Therapeutics, Inc. cheaply via an unfair process.

Philadelphia, PA based Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.

On February 25, 2019, Spark Therapeutics (NASDAQ: ONCE) announced that it has entered into a merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. However, plaintiff claims that the proposed consideration NASDAQ: ONCE shareholders will receive is grossly inadequate and undervalues Spark Therapeutics, Inc. Indeed, at least one analyst has set the high target price NASDAQ: ONCE shares at $115.00 per share. In addition, the plaintiff alleges that the process is also unfair NASDAQ: ONCE stockholders. Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE) closed on March 15, 2019, at $113.59 per share.